ipilimumab,nivolumab,durvalumab,vinorelbine,paclitaxel,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['durva', 'cm816']
neoadjuvant durvalumab over placebo increased pcr rate from 4.3% to 17.2% (+13%) and mpr from 12.3% to 33.3% (+21%). comparable to cm816 (pcr 24%) and note larger sample size here and different methodology to define pcr. awaiting outcomes by pcr status. #aacr23 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast #ITYSL #HereWeGo